loading...| Preferred Name |
dexverapamil |
|
| Synonyms |
R-Verapamil Hydrochloride |
|
| Definitions |
The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1563" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1563" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000041269 |
|
| altLabel |
R-Verapamil Hydrochloride R verapamil R-verapamil |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000041740 http://purl.bioontology.org/ontology/PDQ/CDR0000042150 http://purl.bioontology.org/ontology/PDQ/CDR0000041272 http://purl.bioontology.org/ontology/PDQ/CDR0000041271 |
|
| cui |
C0280858 C1527029 |
|
| Date last modified |
2006-12-12 |
|
| definition |
The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1563" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1563" NCI Thesaurus) |
|
| IND Code |
34790 |
|
| Legacy PDQ ID |
4342 |
|
| NCI ID |
C1563 |
|
| notation |
CDR0000041269 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
dexverapamil |
|
| tui |
T109 T121 |